• Home
  • /
  • Uncategorized
  • /
  • Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in women with HER2 positive advanced breast cancer

Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in women with HER2 positive advanced breast cancer

EAST HANOVER, N.J., June 2, 2013 /PRNewswire/ — Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor® (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received pr